Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).


Open article in different language:  DE  |  FR  |  IT
Art. 3 Scientific integrity

1 The spon­sor and the in­vest­ig­at­or, and the oth­er per­sons in­volved in the clin­ic­al tri­al, shall main­tain sci­entif­ic in­teg­rity. In par­tic­u­lar, it is pro­hib­ited:

a.
to falsi­fy, fab­ric­ate or sup­press re­search res­ults;
b.
to fail to dis­close con­flicts of in­terest at the plan­ning stage, in the au­thor­isa­tion pro­ced­ure, or when con­duct­ing or pub­lish­ing re­search;
c.
to im­pede or pre­vent re­search activ­it­ies without good reas­on;
d.
to pre­vent or sanc­tion the ex­pos­ure of sci­entif­ic mis­con­duct.

2 The ap­plic­able guidelines are the Prin­ciples and Pro­ced­ures for In­teg­rity in Sci­entif­ic Re­search is­sued by the Swiss Academies of Arts and Sci­ences, as spe­cified in An­nex 1 num­ber 1. In jus­ti­fied cases, oth­er re­cog­nised sci­entif­ic in­teg­rity guidelines of equi­val­ent stand­ing may be used.

Diese Seite ist durch reCAPTCHA geschützt und die Google Datenschutzrichtlinie und Nutzungsbedingungen gelten.

Feedback
Laden